A forum for researchers, students and applicants in the field of cyclodextrin technology
Rafael Holdings, Inc. (NYSE: RFL) announced on Oct. 29 that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug
The global, double-blind, placebo-controled Phase 3 TransportNPC™ study (CTD-TCNPC-301) enroled 94 patients with NPC, ranging in age from 3 to
Niemann–Pick disease type C (NPC) and Alzheimer’s disease (AD) are neurodegenerative disorders characterised by cognitive dysfunction and neurological impairment. In
Beren Therapeutics Announced FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann-Pick Disease Type C. Beren Therapeutics
JIC Venture Growth Investments (VGI) announced that it has invested in Beren Therapeutics P.B.C. (“Beren Therapeutics”). Beren Therapeutics is developing
Rafael Holdings, Inc. announced that data from Cyclo Therapeutics’ Phase 3 TransportNPC™ open-label, single-arm sub-study evaluating Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick
Rafael Holdings and Cyclo Therapeutics on Thursday announced a merger agreement as they look to spur development of their Niemann-Pick
This study sought to systematically compare the efficacy and mechanism of cyclodextrins as drug interventions in lipid metabolism diseases, potentially
Niemann–Pick Type C (NPC) represents an autosomal recessive disorder with an incidence rate of 1 in 150,000 live births, classified
Cyclo Therapeutics, (Cyclo) a clinical stage company focused on developing therapies for rare and neurological diseases with limited treatment options,
